A US-based KOL discusses the current autism spectrum disorder treatment landscape, emphasizing the central role of behavioral therapies in addressing core symptoms and the frequent use of pharmacotherapies for managing comorbidities. The KOL notes the absence of medications targeting core deficits like speech and communication, while expressing cautious interest in emerging therapies under investigation. 

This interview was conducted on November 27, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.